Indian Govt. supports augmentation of manufacturing capacity of Covaxin production
This will lead to increase in Covaxin production capacity by more than 10 crore doses per month by September, 2021
In order to augment the production capacity of indigenous vaccine, Covaxin, the Government of India’s Department of Biotechnology has provided financial support as grant to vaccine manufacturing facilities for enhanced production capacities, which is expected to reach more than 10 crore doses per month by September, 2021.
As a part of this augmentation plan, capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufactures are being upgraded with required infrastructure and technology. Financial support is being provided as grant from the Government of India to the tune of approx. Rs 65 Cr to Bharat Biotech’s new Bangalore facility which is being repurposed to increase the capacity of vaccine production.
The following three public sector companies are also being supported to increase the capacity of vaccine production.
Haffkine Biopharmaceutical Corporation Ltd, Mumbai-a State PSE under State Government of Maharashtra. Financial support of Rs. 65 crores as grant from the Government of India is being provided for this facility to make it ready for manufacturing. The facility will have a capacity of 20 million doses per month, once functional.
2. Indian Immunologicals Limited (IIL), Hyderabad –A facility under National Dairy Development Board is being provided a grant of Rs. 60 crore.
3. Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr a CPSE under Department of Biotechnology, Government of India is being supported with a grant of Rs. 30 crores to prepare their facility to provide 10-15 million doses per month.
Further, Gujarat Biotechnology Research Centre, Department of Science and Technology Govt. of Gujarat along with Hester Biosciences and Omni BRx have also firmed up their discussions with Bharat Biotech to scale up the Covaxin technology and to produce minimum 20 million doses per month. Technology transfer agreement has been finalized with all manufacturers.